Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification

Blood

Volumn 95, Issue 5, 2000, Pages 1758-1766

  Le Coutre, Philipp ^b   Tassi, Elena ^b   Varella Garcia, Marileila ^b   Barni, Rossella ^b   Mologni, Luca ^b   Cabrita, Gonçalo ^b   Marchesi, Edoardo ^b   Supino, Rosanna ^b   Gambacorti Passerini, Carlo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; ONCOGENE; PRIORITY JOURNAL;

EID: 0034161460     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.5.1758.005a41_1758_1766     Document Type: Article

References (21)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210BCR/ABL gene of the Philadelphia chromosome. Science. 1990;247:824-830.
2. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukemia in BCR/ABL transganic mice. Nature. 1990;344:251-253.
3. Gaiger A, Henn T, Hört E, et al. Increase of BCR/ ABL chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 1995;86:2371-2378
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
5. Buchdunger E, Zimmerman J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.
6. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mos Dis. 1997;23:380-394.
7. Deininger MWN, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor STI571 selectively inhibits the growth of BCR-ABL positive cells. Blood. 1997;90:3691-3698.
8. Seigneurin D, Champelovier P, Mouchiroud G, et al. Human chronic myeloid leukemic cell line with Philadelphia chromosome exhibits megakaryocytic and erythrocytic characteristics. Exp Hematol. 1987;15:822-832.
9. le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL+ leukemic cells with an ABL kinase inhibitor. J Natl Cancer Inst. 1999;91:163-168.
10. Sausville E. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges. J Natl Cancer Inst. 1999;91:102-103.
11. Martin S, Reutlingsperger CPM, McGahon AJM, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995;182:1545-1556.
12. Mologni L, Ponzanelli I, Bresciani F, et al. The novel synthetic retinoid 6-(3-adamantyl-4-hydroxyphenyl)-2-naphtalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood. 1999;93:1045-1061.
13. Pelicci G, Lanfrancone L, Grignani F, et al. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell. 1992;70:93-104.
14. Van Denderen J, Hermans A, Meeuwsen T, et al. Antibody recognition of the tumor-specific BCR-ABL joining region in chronic myeloid leukemia. J Exp Med. 1989;169:87-98.
15. Drexler HG, MacLeod RAF, Uphoff CC. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk Res. 1999;23:207-215.
16. Perfetti V, Manenti G, Dragani TA. Expression of housekeeping genes in Hodgkin's disease lymph nodes. Leukemia. 1991;5:1110-1112.
17. le Coutre P, Marchesi E, Bertazzoli C, Pogliani E, Gambacorti-Passerini C. Generation of BCR-ABL positive leukemic cell lines resistant to a selective ABL kinase inhibitor. Blood. 1997;90:496a.
18. Göker E, Waltharn M, Kheradpour A, et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood. 1995;86:677-684.
19. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene. 1998;16:335-348.
20. Amarante-Mendes GP, Naekyung Kim C, Liu L, et al. Bcr-Abl exerts its anti-apoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998;91:1700-1705.
21. le Coutre P, Cleris L, Marchesi E, Formelli F, Gambacorti-Passerini C. Eradication of BCR/ ABL+ leukemic cells in nude mice by the Tyrosine Kinase Inhibitor STI571 is dependent on the initial tumor load. Blood. 1998;92:628a.